NCT06871410View on ClinicalTrials.gov

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Autologous Anti-CD83 CAR T-cells

Given IV

PROCEDURE

Biospecimen Collection

Undergo bone marrow aspiration blood sample collection

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Fludarabine Phosphate

Given IV

DRUG

Hydroxyurea

Given hydroxyurea

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Positron Emission Tomography

Undergo PET

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER